Jessica Kaufeld Selected Research

caplacizumab

1/2022	Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
11/2020	Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab.
1/2020	ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.
1/2020	Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jessica Kaufeld Research Topics

Disease

3	Fabry Disease (Fabry's Disease) 01/2022 - 01/2020
3	acquired Thrombotic thrombocytopenic purpura 11/2020 - 01/2020
1	Thrombotic Thrombocytopenic Purpura 01/2022
1	Disease Progression 01/2020
1	Acute Disease 01/2020
1	Ischemia 01/2019
1	Respiratory Insufficiency (Respiratory Failure) 01/2019
1	Low Cardiac Output 01/2019
1	Chronic Limb-Threatening Ischemia 01/2019
1	Cystinosis 01/2018
1	Hypertension (High Blood Pressure) 10/2013
1	Proteinuria 09/2010

Drug/Important Bio-Agent (IBA)

4	caplacizumabIBA 01/2022 - 01/2020
3	GalactosidasesIBA 01/2022 - 01/2020
3	EnzymesIBA 01/2022 - 01/2020
3	globotriaosylceramide (globotriosylceramide)IBA 01/2022 - 01/2020
3	migalastatIBA 01/2022 - 01/2020
1	von Willebrand FactorIBA 01/2022
1	Cystine (L-Cystine)IBA 01/2018
1	Proteins (Proteins, Gene)FDA Link 10/2013
1	Dextrans (Dextran)FDA Link 09/2010

Therapy/Procedure

2	Therapeutics 01/2019 - 01/2018
1	Plasma Exchange 11/2020
1	Extracorporeal Circulation 01/2019
1	Extracorporeal Membrane Oxygenation 01/2019